PHAR Stock Analysis: Buy, Sell, or Hold?
PHAR - Pharming Group N.V. ADS, each representing 10 ordinary shares
$11.21
0.41 (3.75%)
â˛
5d:
-2.18%
30d:
-5.24%
90d:
-12.97%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When PHAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PHAR is fairly priced but lacks strong directional signals. At -42.7% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PHAR is fairly priced but lacks strong directional signals. At -42.7% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$3.27
Based on -14.6% avg growth
INTRINSIC VALUE TODAY
$2.03
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHAR is currently trading at $11.21, which is considered slightly low relative to its 30-day fair value range of $10.98 to $11.94. From a valuation perspective, the stock is trading at a discount (Forward PE: 36.5) compared to its historical average (194.5). Remarkably, the market is currently pricing in an annual earnings decline of 42.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PHAR is in a downtrend. Immediate support is located at $10.65, while resistance sits at $11.81. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: PHAR scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $34.35 (+206.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PHAR is in a downtrend. Immediate support is located at $10.65, while resistance sits at $11.81. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: PHAR scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $34.35 (+206.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$10.98 -
$11.94
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 206.4% below Wall St target ($34.35)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.98 -
$11.94
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$10.65
Resistance Level
$11.81
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
36.51
Wall Street Target
$34.35
(+206.4%)
Revenue Growth (YoY)
-3.2%
Earnings Growth (YoY)
-62.9%
Profit Margin
2.5%
Valuation Discount vs History
-42.7% cheaper
PE vs Historical
36.5 vs 194.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-42.7%
(market-implied from PE analysis)
1-Year Target
$10.09
(-10%)
2-Year Target
$9.08
(-19%)
3-Year Target
$8.17
(-27%)
3-Yr Target (if PE normalizes)
(PE: 37â195)
$43.53
(+288%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 36.5, Growth: -33.3%)
$8.17
(+-27%)
Base:
(SPY PE: 20.2, Growth: -33.3%)
$4.51
(-60%)
Bear:
(PE: 17.1, Growth: -33.3%)
$3.84
(-66%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (77x PE), but valuation improves significantly next year (37x PE) as earnings recover.
Trailing PE: 77.18 | Current EPS (TTM): $0.14
Bull Case
$23.77
(+112%)
Analyst growth 100.0%, PE expands to 84.9
Base Case
$21.61
(+93%)
Market implied 100.0%, PE stable at 77.2
Bear Case
$7.35
(-35%)
Severe decline -20.0%, PE contracts to 65.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 36.5 to 194.5
Stabilization Target:
$59.71
(+432.7%)
PE Expansion Potential:
+432.7%
Share & Embed Analysis
Last updated: September 12, 2026 9:20 PM ET
Data refreshes hourly during market hours. Next update: 10:20 PM
Data refreshes hourly during market hours. Next update: 10:20 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
